Cargando…
Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527537/ https://www.ncbi.nlm.nih.gov/pubmed/30515569 http://dx.doi.org/10.1007/s00432-018-2806-2 |
| _version_ | 1783420042554114048 |
|---|---|
| author | Mizutani, Kosuke Horie, Kengo Kato, Taku Nakane, Keita Kawakami, Kyojiro Fujita, Yasunori Ito, Masafumi |
| author_facet | Mizutani, Kosuke Horie, Kengo Kato, Taku Nakane, Keita Kawakami, Kyojiro Fujita, Yasunori Ito, Masafumi |
| author_sort | Mizutani, Kosuke |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6527537 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65275372019-06-07 Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy Mizutani, Kosuke Horie, Kengo Kato, Taku Nakane, Keita Kawakami, Kyojiro Fujita, Yasunori Ito, Masafumi J Cancer Res Clin Oncol Letter to the Editors Springer Berlin Heidelberg 2018-12-05 2019 /pmc/articles/PMC6527537/ /pubmed/30515569 http://dx.doi.org/10.1007/s00432-018-2806-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Letter to the Editors Mizutani, Kosuke Horie, Kengo Kato, Taku Nakane, Keita Kawakami, Kyojiro Fujita, Yasunori Ito, Masafumi Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy |
| title | Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy |
| title_full | Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy |
| title_fullStr | Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy |
| title_full_unstemmed | Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy |
| title_short | Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy |
| title_sort | serum pd-1 levels measured by elisa using nivolumab increased in advanced rcc patients: novel approach to develop companion diagnostics for antibody therapy |
| topic | Letter to the Editors |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527537/ https://www.ncbi.nlm.nih.gov/pubmed/30515569 http://dx.doi.org/10.1007/s00432-018-2806-2 |
| work_keys_str_mv | AT mizutanikosuke serumpd1levelsmeasuredbyelisausingnivolumabincreasedinadvancedrccpatientsnovelapproachtodevelopcompaniondiagnosticsforantibodytherapy AT horiekengo serumpd1levelsmeasuredbyelisausingnivolumabincreasedinadvancedrccpatientsnovelapproachtodevelopcompaniondiagnosticsforantibodytherapy AT katotaku serumpd1levelsmeasuredbyelisausingnivolumabincreasedinadvancedrccpatientsnovelapproachtodevelopcompaniondiagnosticsforantibodytherapy AT nakanekeita serumpd1levelsmeasuredbyelisausingnivolumabincreasedinadvancedrccpatientsnovelapproachtodevelopcompaniondiagnosticsforantibodytherapy AT kawakamikyojiro serumpd1levelsmeasuredbyelisausingnivolumabincreasedinadvancedrccpatientsnovelapproachtodevelopcompaniondiagnosticsforantibodytherapy AT fujitayasunori serumpd1levelsmeasuredbyelisausingnivolumabincreasedinadvancedrccpatientsnovelapproachtodevelopcompaniondiagnosticsforantibodytherapy AT itomasafumi serumpd1levelsmeasuredbyelisausingnivolumabincreasedinadvancedrccpatientsnovelapproachtodevelopcompaniondiagnosticsforantibodytherapy |